The Federal Antimonopoly Service of Russia has filed a lawsuit against the pharmaceutical company Akrikhin, accusing it of violating the Law on Protection of Competition. This is reported with reference to the order of the head of the FAS Maxim Shaskolsky. RBC.
In April 2024, Akrikhin put into circulation 22 batches of the drug for the treatment of diabetes mellitus Fordiglyf, an analogue of the original drug Forxiga of the British-Swedish company AstraZeneca. The manufacturer of Forxiga considered that Akrikhin’s actions violated a patent valid until 2028.
AstraZeneca says that patent infringement threatens public health in order to make quick profits. The company emphasizes that protecting innovation is necessary to extend life and maintain quality, as well as to encourage investment in new developments. AstraZeneca also considers the filing of the FAS case an important step that should be a guide for the entire industry and stop patent infringement.
Previously AstraZeneca appealed To the Investigative Committee for his diabetes treatment.